Glaukos Co. (NYSE:GKOS) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its stake in Glaukos Co. (NYSE:GKOS) by 45.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 501,511 shares of the medical instruments supplier’s stock after selling 416,645 shares during the quarter. Dimensional Fund Advisors LP owned 1.00% of Glaukos worth $59,352,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Glaukos in the 4th quarter valued at $28,807,000. Allspring Global Investments Holdings LLC lifted its holdings in Glaukos by 148.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock valued at $48,805,000 after purchasing an additional 246,322 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Glaukos in the 4th quarter valued at $15,065,000. Iron Triangle Partners LP raised its holdings in shares of Glaukos by 75.6% during the 1st quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock worth $40,500,000 after acquiring an additional 184,919 shares during the period. Finally, Great Lakes Advisors LLC purchased a new position in shares of Glaukos during the 2nd quarter worth $13,925,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, COO Joseph E. Gilliam sold 2,250 shares of the business’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $121.39, for a total transaction of $273,127.50. Following the completion of the transaction, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at $12,362,964.55. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gilbert H. Kliman sold 3,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The disclosure for this sale can be found here. Insiders sold a total of 41,500 shares of company stock valued at $5,099,000 in the last three months. 6.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. StockNews.com lowered Glaukos from a “hold” rating to a “sell” rating in a report on Friday, August 30th. Needham & Company LLC lifted their price target on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Stifel Nicolaus lifted their price target on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Truist Financial reiterated a “buy” rating and set a $145.00 price target (up previously from $141.00) on shares of Glaukos in a report on Thursday, August 1st. Finally, BTIG Research lifted their price target on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $129.82.

Glaukos Stock Up 0.6 %

Shares of NYSE:GKOS opened at $128.29 on Friday. The business has a 50-day moving average price of $125.39 and a 200 day moving average price of $112.95. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $6.46 billion, a price-to-earnings ratio of -44.55 and a beta of 1.03. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $136.60.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). The company had revenue of $95.70 million during the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. Glaukos’s revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.55) EPS. Sell-side analysts expect that Glaukos Co. will post -2.18 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.